{
"id":"mk19_a_id_t39",
"number":39,
"bookId":"id",
"title":{
"__html":"Immunizations for Travel<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"6ad282",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 39. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t39"
}
]
},
"Immunizations for Travel",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"849219",
"class":"col hd l",
"children":[
"Recommended According to Destination, Itinerary, and Purpose of Travel"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ce9ea",
"class":"cell txt l",
"children":[
"Hepatitis A",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
": first dose as soon as travel is considered, booster at 6-12 months (Havrix) or 6-18 months (Vaqta); or 0, 1 month, and 6 months for HepA-HepB combination (Twinrix)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f21c98",
"class":"cell txt l",
"children":[
"Hepatitis B",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
": 0, 1 month (Heplisav-B",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"); or 0, 1 month, 6 months (Engerix-B, Recombivax-HB); or 0, 1 month, and 6 months for HepA-HepB combination (Twinrix)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7dad43",
"class":"cell txt l",
"children":[
"Typhoid",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
": Live-attenuated oral vaccine (Ty21a); 0, 2 days, 4 days, 6 days; capsular Vi polysaccharide intramuscular vaccine; one dose (preferred for immunocompromised persons)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e63b7",
"class":"cell txt l",
"children":[
"Cholera: Live oral, 10 days before travel; killed oral, whole-cell-B subunit; 0, 1 week (available outside the United States)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2190f4",
"class":"cell txt l",
"children":[
"Rabies: Inactivated; 0, 7 days, 21-28 days"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f8bbc4",
"class":"cell txt l",
"children":[
"Japanese encephalitis: Inactivated; 0, 28 days (booster recommended ≥11 months with ongoing risk)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4af2b9",
"class":"cell txt l",
"children":[
"Polio",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"f"
]
},
": inactivated; single dose (IM or SQ) if primary series completed; two doses 4-8 weeks apart followed by third dose 6-12 months after second if previously unvaccinated"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b16a45",
"class":"cell txt l",
"children":[
"Measles",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"g"
]
},
": live-attenuated, two doses separated by 28 days (born after 1956 and no documentation of vaccination or evidence of immunity)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64c61f",
"class":"cell txt l",
"children":[
"Dengue: three doses given 6 months apart; only in seropositive persons aged 9-45 years (not available in the United States)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8173ba",
"class":"cell txt l",
"children":[
"Tick-borne encephalitis: Inactivated; three doses over 6-15 months, second dose ≥2 weeks after first if rapid immune response required (not available in the United States)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3a8a3",
"class":"col hd l",
"children":[
"Required for Certain Destinations"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eb7ef1",
"class":"cell txt l",
"children":[
"Yellow fever",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"h"
]
},
": Live attenuated; one dose (no booster required)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f7a2a",
"class":"cell txt l",
"children":[
"Meningococcal: Quadrivalent conjugate (MenACWY); one dose and revaccinate every 5 years if the risk persists"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"IM = intramuscular, SQ = subcutaneous."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"All patients being evaluated for travel should receive or be up to date with all scheduled immunizations, including COVID-19, influenza, pneumococcal, tetanus-diphtheria-pertussis, polio, varicella, and zoster vaccines. See ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s1_3",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
" for routine adult immunization recommendations."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"If not received as part of routine scheduled immunizations. If the vaccine series was completed as part of scheduled immunization, repeat immunization is not required."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"HepA-HepB combination (Twinrix) can be administered on an accelerated schedule of 0, 7, and 21-30 days, with a booster at 12 months."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Heplisav-B is contraindicated in pregnancy because of a lack of safety data."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
"Oral vaccine should not be administered within 24 hours of the antimalarial drug mefloquine because of the potential to decrease the vaccine's immunogenicity; patients must not take any antibiotic for at least 72 hours before receiving the vaccine."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"f"
]
},
"If traveling to countries with wild or vaccine-derived poliovirus circulation."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"g"
]
},
"Additional dose if documented to have had one dose but no proof of immunity. See ",
{
"type":"cross-reference",
"target":"mk19_a_id_s19_4",
"children":[
"Viral Infections"
]
},
" for further information."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"h"
]
},
"The approved, live-attenuated yellow fever vaccine is currently unavailable in the United States; another live yellow fever vaccine used in Europe is available as an alternative option in the United States under the FDA's investigational new drug program."
],
[
"Recommendations from the Centers for Disease Control and Prevention. CDC Yellow Book 2020: Health Information for International Travel. New York: Oxford University Press; 2019. Available online at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/malaria",
"target":"_blank"
},
"children":[
"https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/malaria"
]
},
"."
]
]
}